March 3, 2020 / 9:38 AM / a month ago

BRIEF-Destiny Pharma Says Phase 2B Of Nasal Gel Trial Remains On Track

March 3 (Reuters) - Destiny Pharma PLC:

* DESTINY PHARMA- PHASE 2B CLINICAL TRIAL OFXF-73 (EXEPORFINIUM CHLORIDE) NASAL GEL TRIAL REMAINS ON TRACK TO COMPLETE PATIENT RECRUITMENT IN MID2020

* DESTINY PHARMA PLC - HAD AN UNAUDITED CASH POSITION OF £7.5 MILLION AS AT 31 DECEMBER 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below